BACKGROUND: The Gustave Roussy Immune (GRIm)-Score takes into account neutrophil-to-lymphocyte ratio (NLR), serum albumin concentration and lactate dehydrogenase (LDH) and its prognostic value has been investigated in patients treated with immune check-point inhibitors (ICIs). To further assess the prognostic and predictive value of baseline GRIm-Score (GRImT0) in advanced non-small cell lung cancer (aNSCLC) patients, we separately investigated two cohorts of patients treated with first-line pembrolizumab or chemotherapy. We also investigated whether GRIm-Score at 45 days since treatment initiation (GRImT1) and GRIm-Score difference between the two timepoints may better predict clinical outcomes (GRImΔ = GRImT0 - GRImT1). METHODS: We retrospectively evaluated 222 aNSCLC patients: 135 treated with pembrolizumab and 87 treated with chemotherapy as the first-line regimen. NLR, serum albumin and LDH concentrations were assessed at T0 and at T1. According to the GRIm-Score, patients were assigned 1 point if they had NLR > 6, LDH > upper limit normal or albumin < 3.5 g/dL. Patients with a GRIm-Score < 2 were considered as having a low Score. RESULTS: In both cohorts, no difference in terms of overall survival (OS) between patients with low and high GRImT0 was found. Otherwise, median OS and progression free survival (PFS) of the low GRImT1 group were significantly longer than those of the high GRImT1 group in pembrolizumab-treated patients, but not in the CHT cohort (pembrolizumab cohort: low vs. high; median OS not reached vs. 9.2 months, p = 0.004; median PFS 10.8 vs. 2.3 months, p = 0.002). Patients receiving pembrolizumab with stable/positive GRImΔ had better OS (median OS not reached vs. 12.0 months, p < 0.001), PFS (median PFS 20.6 vs. 2.6 months, p < 0.001) and objective response rate (58.2% vs. 7.6%, p = 0.003) compared to patients with negative GRImΔ. CONCLUSION: Our data shown that GRImT1 and GRImΔ are more reliable peripheral blood biomarkers of outcome compared to GRImT0 in aNSCLC patients treated with pembrolizumab and might represent useful biomarkers to drive clinical decisions in this setting.
BACKGROUND: The Gustave Roussy Immune (GRIm)-Score takes into account neutrophil-to-lymphocyte ratio (NLR), serum albumin concentration and lactate dehydrogenase (LDH) and its prognostic value has been investigated in patients treated with immune check-point inhibitors (ICIs). To further assess the prognostic and predictive value of baseline GRIm-Score (GRImT0) in advanced non-small cell lung cancer (aNSCLC) patients, we separately investigated two cohorts of patients treated with first-line pembrolizumab or chemotherapy. We also investigated whether GRIm-Score at 45 days since treatment initiation (GRImT1) and GRIm-Score difference between the two timepoints may better predict clinical outcomes (GRImΔ = GRImT0 - GRImT1). METHODS: We retrospectively evaluated 222 aNSCLC patients: 135 treated with pembrolizumab and 87 treated with chemotherapy as the first-line regimen. NLR, serum albumin and LDH concentrations were assessed at T0 and at T1. According to the GRIm-Score, patients were assigned 1 point if they had NLR > 6, LDH > upper limit normal or albumin < 3.5 g/dL. Patients with a GRIm-Score < 2 were considered as having a low Score. RESULTS: In both cohorts, no difference in terms of overall survival (OS) between patients with low and high GRImT0 was found. Otherwise, median OS and progression free survival (PFS) of the low GRImT1 group were significantly longer than those of the high GRImT1 group in pembrolizumab-treated patients, but not in the CHT cohort (pembrolizumab cohort: low vs. high; median OS not reached vs. 9.2 months, p = 0.004; median PFS 10.8 vs. 2.3 months, p = 0.002). Patients receiving pembrolizumab with stable/positive GRImΔ had better OS (median OS not reached vs. 12.0 months, p < 0.001), PFS (median PFS 20.6 vs. 2.6 months, p < 0.001) and objective response rate (58.2% vs. 7.6%, p = 0.003) compared to patients with negative GRImΔ. CONCLUSION: Our data shown that GRImT1 and GRImΔ are more reliable peripheral blood biomarkers of outcome compared to GRImT0 in aNSCLC patients treated with pembrolizumab and might represent useful biomarkers to drive clinical decisions in this setting.
Authors: Martin Reck; Delvys Rodríguez-Abreu; Andrew G Robinson; Rina Hui; Tibor Csőszi; Andrea Fülöp; Maya Gottfried; Nir Peled; Ali Tafreshi; Sinead Cuffe; Mary O'Brien; Suman Rao; Katsuyuki Hotta; Kristel Vandormael; Antonio Riccio; Jing Yang; M Catherine Pietanza; Julie R Brahmer Journal: J Clin Oncol Date: 2019-01-08 Impact factor: 44.544
Authors: B Besse; A Adjei; P Baas; P Meldgaard; M Nicolson; L Paz-Ares; M Reck; E F Smit; K Syrigos; R Stahel; E Felip; S Peters Journal: Ann Oncol Date: 2014-03-25 Impact factor: 32.976
Authors: Alessio Cortellini; Alex Friedlaender; Giuseppe L Banna; Giampiero Porzio; Melissa Bersanelli; Federico Cappuzzo; Joachim G J V Aerts; Raffaele Giusti; Emilio Bria; Diego Cortinovis; Francesco Grossi; Maria R Migliorino; Domenico Galetta; Francesco Passiglia; Rossana Berardi; Francesca Mazzoni; Vincenzo Di Noia; Diego Signorelli; Alessandro Tuzi; Alain Gelibter; Paolo Marchetti; Marianna Macerelli; Francesca Rastelli; Rita Chiari; Danilo Rocco; Alessandro Inno; Pietro Di Marino; Giovanni Mansueto; Federica Zoratto; Matteo Santoni; Marianna Tudini; Michele Ghidini; Marco Filetti; Annamaria Catino; Pamela Pizzutilo; Luca Sala; Mario Alberto Occhipinti; Fabrizio Citarella; Russano Marco; Mariangela Torniai; Luca Cantini; Alessandro Follador; Vincenzo Sforza; Olga Nigro; Miriam G Ferrara; Ettore D'Argento; Alessandro Leonetti; Linda Pettoruti; Lorenzo Antonuzzo; Simona Scodes; Lorenza Landi; Giorgia Guaitoli; Cinzia Baldessari; Federica Bertolini; Luigi Della Gravara; Maria Giovanna Dal Bello; Robert A Belderbos; Marco De Filippis; Cristina Cecchi; Serena Ricciardi; Clelia Donisi; Alessandro De Toma; Claudia Proto; Alfredo Addeo; Ornella Cantale; Biagio Ricciuti; Carlo Genova; Alessandro Morabito; Daniele Santini; Corrado Ficorella; Katia Cannita Journal: Clin Lung Cancer Date: 2020-06-21 Impact factor: 4.785
Authors: Julie Brahmer; Karen L Reckamp; Paul Baas; Lucio Crinò; Wilfried E E Eberhardt; Elena Poddubskaya; Scott Antonia; Adam Pluzanski; Everett E Vokes; Esther Holgado; David Waterhouse; Neal Ready; Justin Gainor; Osvaldo Arén Frontera; Libor Havel; Martin Steins; Marina C Garassino; Joachim G Aerts; Manuel Domine; Luis Paz-Ares; Martin Reck; Christine Baudelet; Christopher T Harbison; Brian Lestini; David R Spigel Journal: N Engl J Med Date: 2015-05-31 Impact factor: 91.245
Authors: Tony S K Mok; Yi-Long Wu; Iveta Kudaba; Dariusz M Kowalski; Byoung Chul Cho; Hande Z Turna; Gilberto Castro; Vichien Srimuninnimit; Konstantin K Laktionov; Igor Bondarenko; Kaoru Kubota; Gregory M Lubiniecki; Jin Zhang; Debra Kush; Gilberto Lopes Journal: Lancet Date: 2019-04-04 Impact factor: 79.321
Authors: Aixa E Soyano; Bhagirathbhai Dholaria; Julian A Marin-Acevedo; Nancy Diehl; David Hodge; Yan Luo; Rami Manochakian; Saranya Chumsri; Alex Adjei; Keith L Knutson; Yanyan Lou Journal: J Immunother Cancer Date: 2018-11-23 Impact factor: 13.751
Authors: Alessio Cortellini; Biagio Ricciuti; Marcello Tiseo; Emilio Bria; Giuseppe L Banna; Joachim Gjv Aerts; Fausto Barbieri; Raffaele Giusti; Diego L Cortinovis; Maria R Migliorino; Annamaria Catino; Francesco Passiglia; Mariangela Torniai; Alessandro Morabito; Carlo Genova; Francesca Mazzoni; Vincenzo Di Noia; Diego Signorelli; Alain Gelibter; Mario Alberto Occhipinti; Francesca Rastelli; Rita Chiari; Danilo Rocco; Alessandro Inno; Michele De Tursi; Pietro Di Marino; Giovanni Mansueto; Federica Zoratto; Francesco Grossi; Marco Filetti; Pamela Pizzutilo; Marco Russano; Fabrizio Citarella; Luca Cantini; Giada Targato; Olga Nigro; Miriam G Ferrara; Sebastiano Buti; Simona Scodes; Lorenza Landi; Giorgia Guaitoli; Luigi Della Gravara; Fabrizio Tabbò; Serena Ricciardi; Alessandro De Toma; Alex Friedlaender; Fausto Petrelli; Alfredo Addeo; Giampiero Porzio; Corrado Ficorella Journal: J Immunother Cancer Date: 2020-10 Impact factor: 13.751
Authors: Alessio Cortellini; Andrea De Giglio; Katia Cannita; Diego L Cortinovis; Robin Cornelissen; Cinzia Baldessari; Raffaele Giusti; Ettore D'Argento; Francesco Grossi; Matteo Santoni; Annamaria Catino; Rossana Berardi; Vincenzo Sforza; Giovanni Rossi; Lorenzo Antonuzzo; Vincenzo Di Noia; Diego Signorelli; Alain Gelibter; Mario Alberto Occhipinti; Alessandro Follador; Francesca Rastelli; Rita Chiari; Luigi Della Gravara; Alessandro Inno; Michele De Tursi; Pietro Di Marino; Giovanni Mansueto; Federica Zoratto; Marco Filetti; Michele Montrone; Fabrizio Citarella; Maria Vittoria Pensieri; Marco Russano; Luca Cantini; Olga Nigro; Alessandro Leonetti; Paola Bordi; Gabriele Minuti; Lorenza Landi; Alessandro De Toma; Clelia Donisi; Serena Ricciardi; Maria Rita Migliorino; Valerio Maria Napoli; Gianmarco Leone; Giulio Metro; Giuseppe L Banna; Alex Friedlaender; Alfredo Addeo; Corrado Ficorella; Giampiero Porzio Journal: Thorac Cancer Date: 2021-02-01 Impact factor: 3.500
Authors: Yizhen Guo; Lai Wei; Sandip H Patel; Gabrielle Lopez; Madison Grogan; Mingjia Li; Tyler Haddad; Andrew Johns; Latha P Ganesan; Yiping Yang; Daniel J Spakowicz; Peter G Shields; Kai He; Erin M Bertino; Gregory A Otterson; David P Carbone; Carolyn Presley; Samuel K Kulp; Thomas A Mace; Christopher C Coss; Mitch A Phelps; Dwight H Owen Journal: Clin Lung Cancer Date: 2022-01-08 Impact factor: 4.840
Authors: Christoph Minichsdorfer; Andreas Gleiss; Marie-Bernadette Aretin; Manuela Schmidinger; Thorsten Fuereder Journal: Ann Med Date: 2022-12 Impact factor: 5.348